TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Actinogen Medical ( (AU:ACW) ) is now available.
Actinogen Medical announced that its CEO and CFO will present at the Bell Potter Healthcare Conference 2025, highlighting their lead compound, Xanamem, which targets brain cortisol to slow Alzheimer’s progression and treat depression. The company is conducting multiple clinical trials, including the XanaMIA Phase 2b/3 trial for Alzheimer’s and the XanaCIDD Phase 2a trial for depression, with promising results showing significant benefits on depressive symptoms and cognitive function. These developments could strengthen Actinogen’s position in the biotechnology industry and offer new hope for patients with debilitating neurological conditions.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. The company’s lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with potential future applications for Fragile X Syndrome and other conditions. Actinogen aims to address the substantial unmet medical need for improved treatments in these areas.
Average Trading Volume: 3,723,869
Technical Sentiment Signal: Buy
Current Market Cap: A$165.3M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.